Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WuXi PharmaTech To Transfer Biologics Testing And Manufacturing From U.S. AppTec To New China Lab

This article was originally published in PharmAsia News

Executive Summary

BEIJING - While reporting surging earnings growth for the second quarter of 2008, WuXi PharmaTech said the company would begin transferring biologics testing and manufacturing from recently acquired American AppTec Laboratory Services to China

You may also be interested in...



WuXi PharmaTech Lays Off One-fifth Of U.S. Workforce Months After Acquiring American Biologics Firm AppTec

BEIJING - Less than one year after acquiring the U.S.-based biologics outfit AppTec Laboratory Services in a $160-million deal, WuXi PharmaTech's senior management is preparing to lay off one-fifth of AppTec's 500 employees

WuXi PharmaTech Lays Off One-fifth Of U.S. Workforce Months After Acquiring American Biologics Firm AppTec

BEIJING - Less than one year after acquiring the U.S.-based biologics outfit AppTec Laboratory Services in a $160-million deal, WuXi PharmaTech's senior management is preparing to lay off one-fifth of AppTec's 500 employees

Pfizer Increasing Size of China R&D Center, Expanding Virtual Research Network Through Alliances With Chinese Scientists, WuXi PharmaTech

BEIJING - Pfizer is set to ramp up its research and development center in Shanghai and to integrate more Chinese scientists into its worldwide virtual R&D network, including a new research deal with Wuxi PharmaTech, according to senior Pfizer executives in Shanghai and Hong Kong

Related Content

UsernamePublicRestriction

Register

LL1127945

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel